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Abstract
Significant changes in the management of fungaemia have occurred over the last decade with increased use of fluconazole prophylaxis, of
empirical treatment and of echinocandins as first-line agents for documented disease. These changesmay impact the epidemiology of fungaemia.
We present nationwide data for Denmark from 2010 to 2011. A total of 1081 isolates from 1047 episodes were recorded in 995 patients. The
numbers of patients, episodes and recovered isolates increased by 13.1%, 14.5% and 14.1%, respectively, from 2010 to 2011. The incidence rate
was significantly higher in 2011 (10.05/100 000) than in 2010 (8.82/100 000), but remained constant in the age groups 0–79 years. The
incidence rate was highest at the extremes of age and in males. Candida albicans accounted for 52.1% but declined during 2004–11 (p 0.0155).
Candida glabrata accounted for 28% and increased during 2004–2011 (p <0.0001). Candida krusei, Candida tropicalis and Candida parapsilosis
remained rare (3.3–4.2%). The species distribution changed with increasing age (fewer C. parapsilosis andmore C. glabrata) and by study centre.
Overall, the susceptibility rates were: amphotericin B 97.3%, anidulafungin 93.8%, fluconazole 66.7%, itraconazole 69.6%, posaconazole 64.2%
and voriconazole 85.0%. Acquired echinocandin resistancewasmolecularly confirmed in three isolates. The use of systemic antifungals doubled
over the last decade (2002–2011) (from 717 000 to 1 450 000 defined daily doses/year) of which the vast majority (96.9%) were azoles. The
incidence of fungaemia continues to increase in Denmark and is associated with a decreasing proportion being susceptible to fluconazole.
Changes in demography, higher incidence in the elderly and higher antifungal consumption can at least in part explain the changes.
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Introduction
Significant changes in the management of fungaemia have
occurred over the last decade in response to the increasing
number of fungaemia (fungal bloodstream infection) cases and a
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high mortality in patients in whom antifungal treatment has been
delayed [1–8]. In general, antifungal prophylaxis, empirical and
pre-emptive treatment approaches, most often with fluconaz-
ole, have been extensively explored and the echinocandins have
become first-line agents for targeted treatment of documented
invasive candidiasis [1,9–16]. Candida albicans remains the
predominant species. However, there are geographical differ-
ences and changes over time in species distributions. Hence,
Candida glabrata is more common in the northern hemisphere
while Candida parapsilosis is more common in the southern parts
of theworld and in Asia [17]. The intrinsic susceptibility patterns
of thesespecies aredifferent.Hence, primary antifungal regimens
shouldbeadjusted to the local epidemiology. Several papershave
reported possible consequences of changes in management of
fungaemia with respect to the epidemiology and susceptibility
pattern. Previous exposure to fluconazole or caspofungin affects
the species distribution for subsequent candidaemia cases,with a
higher proportion of C. glabrata after one week of fluconazole
and of C. parapsilosis after echinocandin exposure [18–21].
Surveys conducted in Europe have reported C. glabrata propor-
tions from 8 to 22% [22–32]. In this perspective, the surveillance
in Denmark revealed an unexpectedly increasing proportion of
C. glabrata among blood isolates (from 17% in 2004 to 27% in
2009) [1]. Recent reports of echinocandin breakthrough infec-
tions and acquired resistance, particularly in C. glabrata suggest
that acquired resistancemaybeemerging [33–37].Nevertheless,
it remainsuncertainwhether these trends reflect chiefly tertiary-
centre experiences or represent changes that can be translated
into other settings as well.
Under these circumstances close population-based surveil-
lance of epidemiology and susceptibility patterns are important to
place these observations in the correct perspective and to allow
updated treatment recommendations ensuring appropriate initial
treatment, until species identification and susceptibility test results
are available. A nationwide fungaemia surveillance programme
with prospective collection and susceptibility testing of all blood
isolates has been active in Denmark since 2010. It was established
on thebasis of a previous semi-national programme that combined
with retrospective data documented a notably high annual
incidence rate of 8.6 episodes per 100 000 inhabitants in 2004–
09 compared with most other countries [1,5,8,22,23,25,30,38–
42]. The objective of this study was to extend previous
observations in a contemporary and nationwide perspective.
Materials and Methods
Surveillance and population
Thirteen departments of clinical microbiology together serving
the entire country participated in the prospective national
surveillance in 2010–11. These centres and their geographic
capture areas have been specified previously [1]. Isolates were
referred to the National Mycology Reference Laboratory for
verification of species identification and susceptibility testing
(see below). Completeness was ensured through comparison
with local laboratory records.
Two blood culture systems were used: the BacT/ALERT
(BioMerieux, Marcy l’Etoile, France) and the BACTEC (Becton
Dickinson, Franklin Lakes, NJ, USA) blood culture system. In
total 70.8% of the cases were detected using BacT/ALERT and
29.2% using BACTEC. For fungaemia patients with successive
blood culture isolates, separate episodes were included if they
occurred at least 21 days apart or were caused by different
species consistent with our previous reports [1,24,43].
The size of the Danish population increased marginally
(0.47%, from 5 534 738 in 2010 to 5 560 628 in 2011;
www.statistikbanken.dk).
Information on haematological and gastrointestinal cancers
was retrieved at the website http://www.ssi.dk/Sundhedsda
taogit/Dataformidling/Sundhedsdata/Behandling%20ved%20sy
gehuse/Sygehusaktivitet%20pa%20diagnoseniveau.aspx.
Species identification
Species identification at the reference laboratory was based on
colony morphology on chromogenic agar (CHROMagar CO.,
Paris, France), microscopic morphology on corn meal agar and
rice plus Tween agar (SSI Diagnostika, Hillerød, Denmark),
growth at 35 and 43°C, rapid tests for the identification of
Candida dubliniensis and C. glabrata (BICHRO-DUBLI and
Glabrata RTT, Fumouze Diagnostics, Simoco, Denmark) and
assimilation profile by use of a commercial system (ATB
ID32C; bioMerieux). Additionally, matrix-assisted laser
desorption ionization–time of flight mass spectrometry was
gradually implemented during the second year and used as an
additional tool for isolates that were difficult to identify by
conventional methods. If no reliable species diagnosis was
obtained molecular identification was performed as described
below.
Susceptibility testing
Susceptibility testing was carried out for a total of 1060 (98.1%,
amphotericin B and anidulafungin), 468 (43.3%, caspofungin)
and 1062 (98.2%, fluconazole, itraconazole, posaconazole and
voriconazole) isolates, respectively, according to the EUCAST
definitive document E.Def 7.2 [44]; exceptions were ampho-
tericin B and caspofungin, for which Etest (AB bioMerieux,
Herlev, Denmark) and RPMI 2% glucose agar buffered with
MOPS (SSI Diagnostika, Hillerød, Denmark) was used. Man-
ufacturers and stock solutions in DMSO were as follows
(dimethyl sulphoxide (DMSO), D8779, Sigma-Aldrich,
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Vallensbæk Strand, Denmark): fluconazole (Sigma-Aldrich;
10 000 mg/L), itraconazole (Sigma-Aldrich; 5000 mg/L), posa-
conazole (Merck, Sharp and Dohme, Glostrup, Denmark;
5000 mg/L), and anidulafungin and voriconazole (Pfizer A/S,
Ballerup, Denmark; 5000 mg/L). Candida parapsilosis ATCC
22019 and Candida krusei ATCC 6258 was included as a quality
controls in each run. Accepted EUCAST MIC ranges are
previously published [44] whereas the CLSI MIC ranges were
used for Etest results [45]. The following breakpoints (mg/L;
S /R>): amphotericin B: 1/1 [45]; anidulafungin: C. albicans
0.03/0.03, C. glabrata, C. krusei and C. tropicalis 0.064/0.064
[46]; caspofungin: C. albicans, C. krusei and C. tropicalis 0.25/0.5,
C. glabrata 0.125/0.25 and C. parapsilosis and Candida guillier-
mondii: 2/2 [47]; fluconazole: Candida species other than
C. glabrata and C. krusei: 2/4 [48]; itraconazole: 0.125/0.5 [45];
posaconazole: Candida species other than C. glabrata and
C. krusei: 0.064/0.064 [49]; and voriconazole: Candida species
other than C. glabrata and C. krusei: 0.125/0.125 [50]. For
species and antifungal compound combinations for which no
breakpoint has yet been proposed, the proportion of isolates
with MIC below the breakpoint valid for the other species was
reported as the susceptible proportion of the isolates for the
given species. This is mainly done to illustrate the overall
susceptibility of that species/group of fungi and should not be
interpreted as a precise measurement of susceptibility versus
resistance.
Molecular identification and FKS gene sequence analysis (for
selected isolates)
DNA was released from fungal colonies as previously
described [51]. Species identification was performed using
the universal fungal primers (ITS1; CGTAGGTGAACCTG
CGG and ITS4; TCCTCCGCTTATTGATATGC). FKS gene
sequence analysis was performed as previously described [52].
This gene encodes the target enzyme (glucan synthase) for
echinocandins.
Consumption of antifungal compounds
Information concerning overall use of antifungal agents in
Denmark 2000–11 in hospitals and primary health care was
available in defined daily doses (DDD) from the Danish
Medicines Agency at (www.medstat.dk). Similar information
for Norway was available from the Norwegian Institute of
Public Health at http://www.legemiddelforbruk.no/english/.
Statistics
Incidences per 100 000 inhabitants were calculated using the
population sizes for 1 January each year. Numbers of
admissions for each geographical region in Denmark were
reported by the local study participants.
Chi-square test was used for comparison of changes in
incidence rate and species distribution. p-values <0.05 (two-
tailed) were considered statistically significant.
Results
Epidemiology
National data. During 2010–11 a total of 1081 isolates from
1047 episodes of fungaemia were recorded in 995 patients
leading to an annual incidence rate of 9.4/100 000 inhabitants.
The incidence rate was significantly higher in 2011 compared
with 2010 (10.05 and 8.82/100 000 inhabitants, respectively,
p 0.037) (Table 1). The number of patients, episodes and
recovered isolates increased by 13.1%, 14.5% and 14.1%,
respectively, and by 10.8%, 11.4% and 11.8%, comparing the
incidence rate in 2010–11 to that of the preceding 6-year
period (2004–09) (Table 1) [1]. The incidence rate is shown in
Fig 1 in comparison with the similar figures from Norway and
Finland as reported earlier [22,23,39,53].
The median age remained constant over the 2-year period
and compared with the previous 6 years (Table 1). Candida
species accounted for 98.2% of the fungal isolates and
C. albicans was the predominant species (in total 52.1%)
though a continued decline was observed from 2004 to 2011
(p 0.016, Table 1). Candida glabrata was the second most
frequent species (28%) and increased over the study period as
well as compared with the previous years (p <0.0001).
C. krusei, C. tropicalis and C. parapsilosis were rare isolates
(3.3–4.2%) and their occurrence remained stable. The species
distribution did not vary significantly by gender (data not
shown).
The age-specific and gender-specific incidence rates are
shown in Table 2. The highest incidence rates were seen at the
extremes of age (range 0.86–38.17/100 000 inhabitants). Only
1.4% of the patients were below 1 year of age, 3.9% were 1–
29 years of age, 67.8% were 60 years or older, and 42.2%
were 70 years of age or older. The incidence rate was
significantly higher in males than in females (11.7 versus 7.8/
100 000, p  0.0001) with the largest and significant gender
differences for inhabitants 30–39 years and inhabitants older
than 50 years (Table 2). The age-specific incidence was
comparable to those reported in Norway and Finland for
children and younger adults; however, it was remarkably
higher in the 50 + year age group (Fig 2) [22,23,39,53].
Overall, C. albicans and C. parapsilosis accounted for 75% of the
infections in patients <10 years old. Both C. glabrata and
C. krusei were rare in young patients (two with C. glabrata and
three with C. krusei in patients <20 years old). In contrast,
35.9% of the fungaemia isolates were either C. glabrata or
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C. krusei in patients  60 years of age (Table 2). Candida
glabrata was recovered more often at centres using the BacT/
ALERT system (207/685 occasions) than at centres using the
BACTEC system (96/396 occasions; p 0.035).
Polyfungal infections occurred in 30 patients (2.9%).
Twenty-nine of these involved two species whereas one
involved three species. In 24 (80.0%) of these patients
C. albicans or C. dubliniensis was isolated in combination with
another yeast, among which C. glabrata accounted for 12 cases.
However, the majority (24/30; 80.0%) of the polyfungal
infections included at least one species with intrinsic decreased
susceptibility to fluconazole (C. glabrata (18), C. krusei (7),
C. lambica (1), C. glabrata and C. krusei were found together in
two cases). Fifty patients (5.0%) had more than one episode
(median age 60 years, range 0–83 years), none of which
involved selection of isolates with acquired resistance mech-
anisms. In 24 patients the same species was re-isolated after a
median of 53 days (range 22–485 days) whereas at least one
new species (with or without the primary species) was isolated
in 26 cases after a median of 7 days (range 1–217 days).
Candida albicans and C. glabrata were most commonly involved
in a recurrent episode as well as episodes involving new
species and there was no difference in the frequency with
which C. glabrata followed C. albicans or vice versa (six
each). Nor was there a trend among recurrent episodes
towards increasing resistance among the other cases (data not
shown).
Centre-specific data. The incidence rate varied four-fold among
the centres from 3.91 to 16.55/100 000 inhabitants and from
2.38 to 9.84/10 000 hospital discharges (Table 3). The inci-
dence rate was lowest at centres serving district hospitals
2.38–4.82/10 000 and highest at centres serving university
hospitals only 4.40–9.84 (Table 3). Also the species distribu-
tion varied by centre; for example, C. albicans accounted for
45–59% and the proportion of isolates belonging to species
with reduced susceptibility to fluconazole (C. glabrata, C. krusei
and other fungi) varied from 23 to 43% (Table 3). Incidence
rates were found to be higher and the proportion of
C. glabrata and C. krusei lower or equal to the average
( 32%) at centres 1, 8, 10 and 14. In contrast, the highest
TABLE 1. Epidemiology and species distribution of fungaemia in Denmark in 2010 and 2011 compared with the previous 6-year
period.
2004–09a 2010 2011 In total 2010–11
Fungal isolates (no.) 2901 505 576 1081
Episodes (no.) 2820 488 559 1047
Patients (no.) 2694 467 528 995
Median age (years (range and interquartile ages)) 66 (0–98 and 55;74) 67 (0–96 and 55;75) 66 (0–105 and 57;75) 66 (0–105 and 56;75)
Gender (% males) 56.5 59.6 59.4 59.5
Episode rate per 100 000 inhabitants 8.6 8.8 10.1 9.4
Episode rate per 10 000 discharges 4.1 4.1 4.6 4.4
Species distribution
Candida albicans 57.1% 52.9% 51.4% 52.1%
Candida dubliniensis 2.6% 1.8% 1.7% 1.8%
Candida glabrata 21.1% 26.9% 29.0% 28.0%
Candida krusei 4.1% 5.0% 4.7% 4.8%
Candida parapsilosis 3.7% 5.1% 3.3% 4.2%
Candida tropicalis 4.8% 4.0% 4.2% 4.1%
Candida speciesb 2.7% 2.4% 4.2% 3.3%
Non-C. albicans spp. not referred for IDc 2.4% 0.0% 0.0% 0.0%
Other fungid 1.6% 2.0% 1.6% 1.8%
aCompiled from Arendrup et al. [1]
bCandida spp. includes the following species in 2010–11: C. guilliermondii 6, C. inconspicua 1, C. kefyr 6, C. lambica 1, C. lusitaniae 11, C. magnolia 1, C. norvegensis 4, C. orthopsilosis 2,
C. palmioleophila 2 and C. pelliculosa 2.
cNon-albicans denotes isolates that were not C. albicans but not referred to the mycology reference laboratory for species identification.
dOther fungi includes: Cryptococcus neoformans 4, Fusarium oxysporum 1, Fusarium proliferatum 2, Fusarium solani 2, Fusarium sp. 1, Geotrichum candidum 1, Rhodotorula glutinis 1,
Saccharomyces boulardii 1 and Saccharomyces cerevisiae 6.
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FIG. 1. Incidence rate of unique fungal blood stream isolates per
100 000 inhabitants (1992–2011) compared with similar figures from
Norway and Finland as reported earlier [22,23,39,53]. The number of
isolates in Denmark in 1992 was estimated using the number of cases
(57) registered at centres 3, 8, 14 and 15 and the proportion of cases
by which these centres contributed during the years 2004–11 (mean
0.45, range 0.42–0.50) leading to an estimate of 127 cases (range 113–
136) in a population of 5 162 126 in 1992.
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proportion (>40%) of C. glabrata and C. krusei were found at
centres 2, 3, 4, 5–7 and 12, for which the incidence rates were
lower than the average (Table 3).
Antifungal susceptibility
If adopting the breakpoints for Candida spp. and other fungi for
which no species-specific breakpoints have been established,
the proportion of isolates that were susceptible was 97.3% for
amphotericin B, 93.8% for anidulafungin, 84.4% for caspofungin,
66.7% for fluconazole, 69.6% for itraconazole, 64.2% for
posaconazole and 85.0% for voriconazole (Table 4).
Most species and isolates were susceptible to amphotericin
B (Table 4). Exceptions were C. krusei and the group of other
fungi for which 73.1% and 68.4% were susceptible, respec-
tively. However, for the majority of the non-susceptible
C. krusei isolates the MIC was 2 mg/L (11/14 isolates, 78.6%)
and no isolates were found with amphotericin MICs above
4 mg/L. Hence, these isolates did not truly separate from the
wild-type population (Table 4). On the contrary, the MICs for
other fungi formed a tri-modal distribution with six isolates
separating from the rest of the isolates, including five isolates
of Fusarium and one of Geotrichum.
Overall, the susceptibility to echinocandins was high.
Caspofungin microdilution testing has been associated with
an unacceptable lot to lot variation prohibiting the selection of
meaningful breakpoints. Therefore, caspofungin susceptibility
testing with Etest was used in 2010 before the EUCAST
anidulafungin breakpoint was established and recommended as
a marker of echinocandin susceptibility in 2011 [46]. Com-
paring the proportion of isolates classified as anidulafungin
versus caspofungin susceptible by species two discrepancies
were observed. First, fewer C. glabrata and C. krusei isolates
were classified as susceptible to caspofungin (65% and 28%,
respectively) than to anidulafungin (99.3% and 100%, respec-
tively) and second, all C. parapsilosis and C. guilliermondii were
classified as susceptible to caspofungin but not to anidulafungin
because of the different recommendations and breakpoints for
CLSI and EUCAST (Table 4). The risk of misclassifying
susceptible wild-type isolates of C. glabrata and C. krusei as
non-susceptible using caspofungin Etest and CLSI breakpoints
has recently been addressed, and the apparent discrepancy
between the proportion of isolates that are classified as
susceptible to caspofungin and anidulafungin among these two
species is likely to be a laboratory issue rather than a true
difference in antifungal activity [54]. Two C. glabrata isolates
were classified as echinocandin resistant because of anidula-
fungin MICs of 0.125 mg/L. For one of these, FKS1 and FKS2
sequencing revealed a S663P alteration in hot spot 1 of the
FKS2p protein. Additionally, one C. tropicalis isolate was
anidulafungin and caspofungin resistant (MIC 0.25 mg/L and
>32 mg/L, respectively) and harboured a heterozygous S80S/P
TABLE 2. Incidence rate (per 100 000 inhabitants) and species distribution by age and gender in the 2-year period 2010–11
Age group (years)
<1 1–9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80–89 90–99 100+ In total
Incidence 12.65 1.09 0.86 1.31 3.14 5.10 11.51 20.29 38.17 36.82 25.36 55.56 9.4
Female 2010–11 12.93 0.69 0.74 0.79 1.77 4.36 9.25 15.89 30.61 24.04 16.47 66.05 7.83
Male 2010–11 10.76 1.49 0.98 1.84 4.47 5.82 13.80 24.84 48.10 57.68 53.86 0.00 11.69
p value (Chi
square approximation)
NS NS NS NS 0.0055 NS 0.0139 0.0003 <0.0001 <0.0001 0.0136 NS <0.0001
No. isolates 15 13 12 17 46 83 165 277 295 140 19 1 1081
Proportion (%) 1.4 1.2 1.1 1.6 4.3 7.7 15.3 25.6 27.3 13.0 1.8 0.1 100.0
Species distribution
Candida albicans 60.0% 61.5% 50.0% 47.1% 45.7% 45.8% 57.6% 52.0% 53.9% 47.9% 42.1% - 52.1%
Candida dubliniensis 0.0% 0.0% 8.3% 5.9% 2.2% 3.6% 3.0% 1.4% 1.0% 0.7% 0.0% - 1.8%
Candida glabrata 6.7% 0.0% 8.3% 23.5% 17.4% 19.3% 25.5% 29.6% 28.8% 37.9% 52.6% 1/1 28.0%
Candida krusei 0.0% 15.4% 8.3% 5.9% 4.3% 10.8% 3.0% 6.1% 3.7% 2.9% 0.0% - 4.8%
Candida parapsilosis 13.3% 15.4% 8.3% 5.9% 2.2% 4.8% 1.2% 4.3% 6.1% 2.9% 0.0% - 4.2%
Candida tropicalis 6.7% 0.0% 0.0% 0.0% 13.0% 9.6% 4.2% 2.2% 3.4% 3.6% 5.3% - 4.1%
Candida speciesa 13.3% 7.7% 0.0% 5.9% 2.2% 4.8% 5.5% 3.6% 1.7% 2.1% 0.0% - 3.3%
Other fungib 0.0% 0.0% 16.7% 5.9% 13.0% 1.2% 0.0% 0.7% 1.4% 2.1% 0.0% - 1.8%
aCandida spp. includes the following species in 2010–11: C. guilliermondii 6, C. inconspicua 1, C. kefyr 6, C. lambica 1, C. lusitaniae 11, C. magnolia 1, C. norvegensis 4, C. orthopsilosis 2,
C. palmioleophila 2 and C. pelliculosa 2.
bOther fungi includes: Cryptococcus neoformans 4, Fusarium oxysporum 1, Fusarium proliferatum 2, Fusarium solani 2, Fusarium sp. 1, Geotrichum candidum 1, Rhodotorula glutinis 1,
Saccharomyces boulardii 1 and Saccharomyces cerevisiae 6.
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FIG. 2. Age-specific incidence rate of unique fungal bloodstream
isolates per 100 000 inhabitants compared with the similar figures
from Norway and Finland as reported earlier [22,23,39,53].
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hot spot alteration [55]. Finally, the proportion of other fungi
that were classified as echinocandin susceptible was low and
limited to Saccharomyces isolates.
For the azoles all C. albicans and C. dubliniensis isolates were
fluconazole susceptible except three C. albicans isolates with
fluconazole MICs of  32 mg/L. Two of these were also highly
resistant to the other three azoles (MICs of 2 mg/L for
itraconazole, posaconazole and voriconazole) whereas the
MIC for one isolate was borderline (itraconazole, posaconaz-
ole and voriconazole MICs of 0.25, 0.25 and 0.125 mg/L,
respectively). Similarly, one C. tropicalis was fluconazole resis-
tant and posaconazole resistant (MICs 8 mg/L and 0.25 mg/L,
respectively), intermediate to itraconazole (MIC 0.25 mg/L)
and had the voriconazole MIC in the upper susceptibility range
of 0.125 mg/L. The azole MICs for C. glabrata, C. krusei and
other fungi were in general elevated compared with those for
C. albicans (Table 4). For C. glabrata in particular, the MIC
distribution was somewhat asymmetric with a tail of isolates
spanning a wide concentration range to the right of the peak
and 13.8% (41/298)  32 mg/L, suggesting that a proportion of
these isolates may harbour acquired resistance mechanisms
(Table 4). Among Candida spp., fluconazole MICs for C. guil-
liermondii, C. lambica, C. palmioleophila, C. pelliculosa, C. norveg-
ensis, C. inconspicua and C. magnolia were consistently >2 mg/L
and for the majority of these isolates MICs were also elevated
for itraconazole and posaconazole, as reflected by the similar
proportion of isolates being classified as susceptible if adopting
the breakpoints for these species (57.1%, 62.9% and 65.7% for
fluconazole, itraconazole and posaconazole, respectively,
whereas this was somewhat higher for voriconazole (88.6%)
(Table 4). Similarly, more isolates in the group of other fungi
were classified as voriconazole susceptible than susceptible to
the other three azoles if applying the Candida breakpoints.
However, this difference reflected that more Saccharomyces
isolates were classified as susceptible to voriconazole. For the
six Fusarium isolates the MICs were as follows: fluconazole
>16 mg/L, itraconazole  4 mg/L, posaconazole 0.25 to
 4 mg/L and voriconazole 1–4 mg/L.
Consumption of antifungals. The national use of systemic
antifungal compounds was investigated as the use in the
primary as well as the hospital setting may impose a selection
pressure on the colonizing fungal flora and species distribution
of subsequent fungaemia isolates. During the 2-year study
period a total of 10 423 000 DDD was prescribed (939 DDD/
1000 inhabitants/year) (Fig 3). Excluding terbinafine, a total of
2 841 000 DDD was used (256 DDD/1000 inhabitants/year)
of which 72% was prescribed in the primary healthcare setting.
For comparison, in Norway the total consumption of systemic
antifungal compounds excluding terbinafine was 70.6 DDD/T
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TABLE 4. Susceptibility of the fungaemia isolates to seven systemic antifungal compounds by species. The MIC was determined
by EUCAST reference methodology (anidulafungin, fluconazole, itraconazole, posaconazole and voriconazole) or by Etest
(amphotericin and caspofungin). Grey boxes indicate concentrations not tested. The official EUCAST breakpoints were adopted
for interpretation except for caspofungin and itraconazole for which the revised CLSI breakpoints were applied. These are
indicated by solid lines. For species and compounds without breakpoints the proportion below the breakpoint for the other
species (dotted lines) is indicated in parenthesis as an indication of the susceptibility profile for the given species/group of isolates
(and a rough estimate of the proportion of cases that are likely good targets for the compound in question).
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1000 inhabitants/year in 2010 and 2011; the majority thereof
was fluconazole (63.7 DDD/1000 inhabitants/year) (http://
www.legemiddelforbruk.no/english/).
The main drug class used in the hospital setting in Denmark
was the azoles (713 000 DDD, 88.2% of the hospital antifungal
use)with fluconazole being themost frequently prescribed agent
(587 000 DDD, 72.6% of the hospital use) followed by
voriconazole (68 000 DDD, or 8.4% of the hospital use) (Fig 3).
Amphotericin B formulations constituted 6.8% of the hospital
use (55 000/808 000 DDD) followed by the echinocandins
3.5% (28 000/808 000 DDD) among which the vast majority
was caspofungin. Of note, the azole use in the hospital setting
constituted only 25.9% of the national use, because of the
extensive use in the primary healthcare sector of fluconazole
and itraconazole. Consumption of the other agents, again
excluding terbinafine, was mainly in the hospital setting (Fig 3).
Discussion
The most important findings in this nationwide fungaemia
surveillance programme are a continuously increasing incidence
rate reaching 10/100 000 inhabitants in 2011, a continuously
changing species distribution with a shift towards species,
particularly C. glabrata, with intrinsic reduced susceptibility to
azoles and a low prevalence of acquired resistance.
In the early 1990s the incidence rate in Denmark was
around 2/100 000 and comparable with the other Nordic
countries [39,53]. It has increased since then and more
conspicuously than in the neighbouring countries
[1,23,24,39,43]. In a recent nationwide study covering 2004–
09 the mean annual incidence rate was 8.6/100 000 with a peak
incidence rate in 2007 and a modest decline thereafter [1].
However, the data for the last 2 years show a further increase
in the incidence rate that appears to be a continuation of the
trend observed since the early 1990s. The age-specific and
gender-specific incidence rates in this study are comparable
with those reported in our previous studies with the notable
exception of the population above 80 years of age and
particularly among males in this age group [1]. Hence, the
main driver of the increasing incidence rate over the last years
in Denmark appears to be a changing demography with a
growing proportion of the elderly. Likewise, it is noticeable
that the age-specific incidence rate was comparable across the
Nordic countries and among males and females in the young
population whereas the elderly population in Denmark and
especially men distinguished themselves from their Nordic
counterparts [23,39]. Important underlying diseases like gas-
trointestinal cancer and leukaemia are more common in the
elderly population and also 34% more common in men
compared with women (according to number of hospital
admissions), which may at least in part explain the gender
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specific differences and changing epidemiology (http://www.ssi.
dk/Sundhedsdataogit/Dataformidling/Sundhedsdata.aspx).
Together, these observations suggest that underlying host
factors rather than genetic differences in susceptibility to fungal
bloodstream infection explain the differences in the incidence
rate among the countries today and are compatible with
differences in co-morbidity and frailty. This is also consistent
with differences in longevity between populations in the
Nordic countries (http://www.norden.org/en/publications/pub-
likationer/2011-001).
Candida albicans and C. parapsilosis were the predominant
species in children, whereas C. glabrata became increasingly
frequent by age in agreement with previous observations
[1,39,42]. Nevertheless, we report for the first time that more
than half of the isolates are non-albicans species in several of the
age-groups and that C. glabrata alone accounted for as many as a
third to one-half of the isolates from patients more than
80 years old. Candida glabrata was found more frequently at
centres using the BacT/ALERT system in agreement with
previous observations suggesting the BACTEC may be less
sensitive for the detection of this species [1,24,56]. Therefore
the fact that the number of centres that use the BACTEC system
has decreased from six to two from 2004 to 2011 may have
contributed to the increased detection of this species. From this
perspective it is important that a previous study demonstrated
a significantly better outcome for patients with C. glabrata
when the initial treatment was caspofungin rather than fluco-
nazole, an observation that is in agreement with findings by
others [18,57]. Hopefully the publication of the recent Euro-
pean and American candidiasis guidelines will lead to better
outcome for this significant patient population [16,58–63].
The incidence rate and species distribution varied between
the participating centres. For the first time a C. albicans
proportion <50% and a combined proportion of C. glabrata
and C. krusei exceeding 40% were found at many centres. An
inverse relationship between the incidence rate and the
proportion of cases involving C. glabrata or C. krusei was
observed, suggesting that the use of azole prophylaxis may be a
significant driver of the centre variation in incidence rate and
species distribution. In this context it is important to note that
the azole use in Denmark is notably higher than in Norway on
the national level and that the vast majority is prescribed in the
primary healthcare sector and for rather benign conditions.
Examples are itraconazole for skin and nail infection where
either topical agents or terbinafine could be used, and systemic
fluconazole or itraconazole for vaginitis where topical azoles
are valid alternatives. Changes to prescription practices are
warranted to reduce the selection pressure on the normal
colonizing flora from which most invasive fungal infections
originate [64].
Acquired resistance was a rare event and limited to a few
C. albicans isolates with azole resistance and a few C. glabrata
and C. tropicalis isolates with echinocandin resistance, as doc-
umented by detection of underlying FKS hot spot mutations
[55]. In recent years echinocandin resistance in particular has
attracted attention because of its emergence in some settings
and because echinocandins are now the first-line agent for
invasive candidiasis [33–35,65–67]. In this perspective the
finding of only a few isolates with acquired resistance among a
thousand cases is reassuring and suggests that species identi-
fication in this setting is more important than susceptibility
testing, in contrast with recent findings [68]. However, the
design of the surveillance programme is not sensitive with
respect to detection of emerging resistance as only the initial
isolate from each episode is included. This is typically obtained at
a time-point with the lowest antifungal exposure and particu-
larly so for the echinocandins, which are mainly used for
documented invasive infections. From an epidemiological point
of view, this is a sound strategy because inclusion of multiple
isolates per patient would lead to bias and skew the epidemi-
ological data set. Only a prospective cohort study of fungaemia
patients with inclusion of subsequent isolates can determine
whether we have just detected the tip of the resistance iceberg.
That this may be a relevant concern is suggested by discrep-
ancies found between the resistance rates among deep-seated
isolates and mucosal isolates in a recent study [69].
The major limitations related to this study are the lack of
data on comorbidities, previous antifungal drug exposure,
and whether fungaemia was nosocomial or of community-
onset. In spite of this the study has highlighted several
important findings and will form the basis for further studies
with the goal of addressing these issues in a nationwide
perspective.
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